Chunghwa Chemical Synthesis & Biotech Dividends and Buybacks
Dividend criteria checks 3/6
Chunghwa Chemical Synthesis & Biotech is a dividend paying company with a current yield of 2.36% that is well covered by earnings.
Key information
2.4%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | 2.4% |
| Dividend Growth | -3.1% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | NT$0.800 |
| Payout ratio | 64% |
Recent dividend and buyback updates
Recent updates
Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 22
Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet
Nov 14Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry
Aug 09Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80
Jul 12Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Apr 01Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 04What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend
Jan 28Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?
Jan 02The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It
Dec 06Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 1762's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1762's dividend payments have fallen over the past 10 years.
Dividend Yield vs Market
| Chunghwa Chemical Synthesis & Biotech Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (1762) | 2.4% |
| Market Bottom 25% (TW) | 1.8% |
| Market Top 25% (TW) | 4.6% |
| Industry Average (Pharmaceuticals) | 2.3% |
| Analyst forecast (1762) (up to 3 years) | 2.4% |
Notable Dividend: 1762's dividend (2.36%) is higher than the bottom 25% of dividend payers in the TW market (1.79%).
High Dividend: 1762's dividend (2.36%) is low compared to the top 25% of dividend payers in the TW market (4.57%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (63.6%), 1762's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (34.6%), 1762's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:35 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chunghwa Chemical Synthesis & Biotech Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Ryan Liu | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |